We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current ACRS market cap is 92.2M. The company's latest EPS is USD -1.2475 and P/E is -1.05.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 19.02M | 7.75M | 2.53M | 1.87M | 9.28M |
| Operating Income | -18.67M | -21.98M | -30.72M | -33.32M | -29.88M |
| Net Income | -19.95M | -27.64M | -28.16M | -29.57M | -29.26M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 4.23M | 6.48M | 6.76M | 29.75M | 31.25M |
| Operating Income | -111.06M | -50.91M | -65.38M | -85.15M | -124.26M |
| Net Income | -161.35M | -51.02M | -90.87M | -86.91M | -88.48M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 267.63M | 254.6M | 229.71M | 235.65M | 218.35M |
| Total Liabilities | 47.79M | 56.98M | 52.9M | 55.9M | 62.02M |
| Total Equity | 219.84M | 197.62M | 176.81M | 179.75M | 156.33M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 98.3M | 70.78M | 251.21M | 254.6M | 197.41M |
| Total Liabilities | 28.39M | 33.13M | 53.87M | 56.98M | 40.23M |
| Total Equity | 69.91M | 37.65M | 197.34M | 197.62M | 157.18M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -48.45M | -67.57M | -26.35M | -47.01M | -71.56M |
| Investing | 9.93M | 12.63M | 25.8M | 6.14M | 38.67M |
| Financing | 72.83M | 72.87M | N/A | 26.74M | 26.66M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -96.45M | -38.63M | -52.13M | -67.57M | -78.33M |
| Investing | 105.68M | 6.39M | -167.63M | 12.63M | 46.22M |
| Financing | -30.32M | 18.37M | 225.05M | 72.87M | 26.71M |
| Market Cap | 92.2M |
| Price to Earnings Ratio | -1.05 |
| Price to Sales Ratio | 2.97 |
| Price to Cash Ratio | 2.33 |
| Price to Book Ratio | 0.59 |
| Dividend Yield | - |
| Shares Outstanding | 70.93M |
| Average Volume (1 week) | 927.22k |
| Average Volume (1 Month) | 757k |
| 52 Week Change | -85.87% |
| 52 Week High | 11.12 |
| 52 Week Low | 0.5902 |
| Spread (Intraday) | 0.07 (5.3%) |
| Company Name | Aclaris Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.aclaristx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
